Tracking newer bowel disease medications when older ones stop working

Plain-English translation of NCT07198113 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated June 2026 · How we translate trials

What is this trial?

COMPARE is a study following children with Crohn's disease or ulcerative colitis who are starting newer medications like vedolizumab, ustekinumab, risankizumab, guselkumab, mirikizumab, tofacitinib, or upadacitinib. These medications are being studied to see how well they work and how safe they are when given to children whose previous treatment stopped helping them.

Many children with inflammatory bowel disease don't respond well to older biologic medications. Doctors need to understand how these newer treatment options work in real-world practice and whether they are safe and effective for children.

Do you qualify?

You likely qualify if…

you are under 18 years old at the time of enrollment
you have been diagnosed with Crohn's disease, ulcerative colitis, or IBD-unclassified
you did not respond to or lost response to at least one anti-TNF medication
you are planning to start one of the study medications for the first time as your next treatment
you or your parent/guardian can give informed consent in English or Spanish

You likely don't qualify if…

you are planning to move to a different medical center within the next year
you have previously taken any of the study medications
you have a medical reason why you cannot take the study medications
you have had your colon surgically removed (for ulcerative colitis patients)
you currently have an ostomy (surgically created opening for bowel drainage)

What participation looks like

You will start your new medication as part of your regular care, and the study will follow you for 1 to 3 years. You'll complete short surveys about how you're feeling every 2 months during the first year, then every 6 months after that. The study will also review your medical records from routine clinic visits, telehealth appointments, and lab work — no extra visits are required beyond your normal doctor appointments.

AI-generated summary from trial data · Jun 2, 2026 · Not medical advice

Trial locations(4 sites)

United States

University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Atrium Health, Charlotte, North Carolina

Duke Health System, Durham, North Carolina

University of Pittsburgh Medical Center, Children's Hospital, Pittsburgh, Pennsylvania